home / stock / obsv / obsv news

OBSV News and Press, ObsEva SA From 07/08/19

Stock Information
Company Name: ObsEva SA
Stock Symbol: OBSV
Market: NASDAQ
Website: obseva.com
Menu
OBSV OBSV Quote OBSV Short OBSV News OBSV Articles OBSV Message Board
Get OBSV Alerts

News, Short Squeeze, Breakout and More Instantly...
OBSV - ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 1 Phase 3 Clinical Trial of Linzagolix for the Treatment of Heavy Menstrual Bleeding Associated with Uterine Fibroids

Geneva, Switzerland and Boston, MA – July 8, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductiv...
OBSV - New medical chief at ObsEva

ObsEva SA (NASDAQ: OBSV ) appoints Dr. Elizabeth Garner as its new Chief Medical Officer (CMO) and member of the Executive Committee, effective July 15. Dr. Garner will be based in the US. More news on: ObsEva SA, Healthcare stocks news, Read more ...

OBSV - ObsEva appoints industry expert as Chief Medical Officer to further advance its Phase 3 clinical programs

  Geneva, Switzerland and Boston, MA – July 1, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s ...

OBSV - Midday Gainers / Losers

Gainers: Axovant Gene Therapies (NASDAQ: AXGT ) +40% . ContraVir Pharmaceuticals (NASDAQ: CTRV ) +24% . India Globalization Capital (NYSEMKT: IGC ) +17% . Pintec Technology (NASDAQ: PT ) +14% . ObsEva SA (NASDAQ: OBSV ) +12% . Overstock.com (NASDAQ: OSTK ) +12% . Fuwei Films (NASDAQ...
OBSV - ObsEva SA to Present Nolasiban and Linzagolix Clinical Data at the ESHRE Annual Meeting June 23-26 in Vienna

Geneva, Switzerland and Boston, MA – June 21, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive heal...

OBSV - ObsEva advances Phase 3 trial for nolasiban following FDA meeting

ObsEva (NASDAQ: OBSV ) announces that its recent End-of-Phase 2 (EOP2) meeting with the FDA provided clarification on key development issues for its oral oxytocin receptor antagonist nolasiban. More news on: ObsEva SA, Healthcare stocks news, Read more ...

OBSV - ObsEva Progressing Toward U.S. Phase 3 Trial for Nolasiban in IVF Following Recent FDA Meeting

Geneva, Switzerland and Boston, MA – June 19, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive h...
OBSV - ObsEva (OBSV) Presents At 2019 Jefferies Global Healthcare Conference - Slideshow

The following slide deck was published by ObsEva SA in conjunction with this Read more ...

OBSV - ObsEva SA Announces Completion of Patient Recruitment in IMPLANT 4 Phase 3 Clinical Trial of Nolasiban for Improving IVF Outcomes

Geneva, Switzerland and Boston, MA – June 4, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductiv...

OBSV - ObsEva SA (OBSV) CEO Ernest Loumaye on Q1 2019 Results - Earnings Call Transcript

ObsEva SA (OBSV) Q1 2019 Results Earnings Conference Call May 09, 2019 08:00 AM ET Company Participants Mario Corso - Senior Director, Investor Relations Ernest Loumaye - Co-Founder and Chief Executive Officer Jean-Pierre Gotteland - Chief Scientific Officer Wim Souverijns - Ch...
Previous 10 Next 10